posted on 2020-07-08, 08:25authored byValentina Thomas, Maura B. Cotter, Miriam Tosetto, Yi Ling Khaw, Robert Geraghty, Desmond C. Winter, Elizabeth J. Ryan, Kieran Sheahan, Simon J. Furney
Synchronous colorectal cancers (syCRCs) are two or more primary tumours identified
simultaneously in a patient. Previous studies report high inter-tumour heterogeneity
between syCRCs, suggesting independent origin and different treatment response,
making their management particularly challenging, with no specific guidelines currently in
place. Here, we performed in-depth bioinformatic analyses of genomic and transcriptomic
data of a total of eleven syCRCs and one metachronous CRC collected from three patients. We found mixed microsatellite status between and within patients. Overlap of mutations between synchronous tumours was consistently low (<0.5%) and heterogeneity of driver events across syCRCs was high in all patients. Microbial analysis revealed the presence of Fusobacterium nucleatum species in patients with MSI tumours, while quantification of tumour immune infiltration showed varying immune responses between syCRCs. Our results suggest high heterogeneity of syCRCs within patients but find clinically actionable biomarkers that help predict responses to currently available targeted therapies. Our study highlights the importance of personalised genome and transcriptome
sequencing of all synchronous lesions to aid therapy decision and improve management
of syCRC patients.
History
Publication
npj Genomic Medicine;5,27
Publisher
Nature Research
Note
peer-reviewed
Other Funding information
St. Vincent’s Foundation Cancer Fund, Ireland Health Foundation